NCT01316302View on ClinicalTrials.gov

12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2012

Conditions
Social Anxiety Disorder
Interventions
DRUG

Pristiq

Flexible dose, 50-100mg QD, for 12 weeks.

DRUG

Placebo

Matching placebo, taken QD for 12 weeks.

Trial Locations (1)

10128

The Medical Research Network, LLC, New York

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

The Medical Research Network

OTHER

NCT01316302 - 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder | Biotech Hunter | Biotech Hunter